January 26, 2025 02:16 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
People of Delhi are waiting for your world-famous dip: Amit Shah attacks Arvind Kejriwal over Yamuna cleaning promise | India will take back nationals illegally staying in the US or elsewhere: MEA | 'We'll get it permanently fixed': Donald Trump tours California to inspect LA fire destruction | US Supreme Court clears 26/11 Mumbai terror attack convict Tahawwur Rana's extradition to India | Narendra Modi to attend Artificial Intelligence Action Summit in France, confirms MEA | Indian students in US are quitting part-time jobs amid Donald Trump's deportation plans: Report | Ensure fair proceedings: Suspended MPs to Lok Sabha Speaker after Waqf bill panel meet row | Saif Ali Khan's attacker Shariful Islam's police custody extended till January 29 | Ordnance factory blast in Maharashtra leaves 8 dead | Heard screams from Jeh's room: Saif Ali Khan records statement with police on stabbing incident
Johnson&Johnson Vaccine

Kolkata's Peerless Hospital commences Johnson & Johnson vaccine's clinical trial

| @indiablooms | May 08, 2021, at 03:50 am

Kolkata/IBNS: Kolkata's Peerless Hospital has been selected as the only trial venue in the East for Johnson & Johnson for their single-dose vaccine which is currently being used under emergency authorization.

In a statement Dr Subhrajyoti Bhowmick, Clinical trial specialist and clinical Pharmacologist and Director, Clinical Research Peerless Hospital, Kolkata said, " We shall be recruiting 100 participants at this site, six such sites have been selected for this trial of this unique single dose vaccine."

"I am confident we shall get enough volunteers for the clinical trial as vaccine supply is short and the supply of Covishield and Covaxine is less than the huge demand. The ratio shall be 3:1 as three volunteers will get a vaccine while one person shall get a placebo. We are now awaiting the ethics committee approval on which we shall embark on the clinical trials," concluded Bhowmick.

Earlier, Sputnik V, developed by Gamaleya Research Institute of Epidemiology and Microbiology in Russia, has been approved for use in India.

Five million doses of Sputnik V are expected to arrive in India by June.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.